[
    "<C> The American Joint Committee on Cancer (AJCC) </C> <A> published </A> <E> the TNM Staging System for the Larynx in 2017 </E>.",
    "<C> The 8th edition of the TNM Staging System for the Larynx </C> <A> was published </A> <E> in 2017 </E>.",
    "<C> The TNM Staging System for the Larynx </C> <E> does not include nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone and cartilage, and mucosal melanoma </E>.",
    "<C> The Primary Tumor (T) category in the TNM Staging System for the Larynx </C> <E> has several subcategories </E>.",
    "<C> TX </C> <E> means the primary tumor cannot be assessed </E>.",
    "<C> Tis </C> <E> means carcinoma in situ </E>.",
    "<C> T1 in the supraglottis category </C> <E> means the tumor is limited to one subsite of supraglottis with normal vocal cord mobility </E>.",
    "<C> T2 in the supraglottis category </C> <E> means the tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis </E>.",
    "<C> T3 in the supraglottis category </C> <E> means the tumor is limited to the larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage </E>.",
    "<C> T4 in the supraglottis category </C> <E> means the tumor is moderately advanced or very advanced </E>.",
    "<C> T4a in the supraglottis category </C> <E> means the tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx </E>.",
    "<C> T4b in the supraglottis category </C> <E> means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures </E>.",
    "<C> T1 in the glottis category </C> <E> means the tumor is limited to the vocal cord(s) with normal mobility </E>.",
    "<C> T1a in the glottis category </C> <E> means the tumor is limited to one vocal cord </E>.",
    "<C> T1b in the glottis category </C> <E> means the tumor involves both vocal cords </E>.",
    "<C> T2 in the glottis category </C> <E> means the tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility </E>.",
    "<C> T3 in the glottis category </C> <E> means the tumor is limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage </E>.",
    "<C> T4 in the glottis category </C> <E> means the tumor is moderately advanced or very advanced </E>.",
    "<C> T4a in the glottis category </C> <E> means the tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx </E>.",
    "<C> T4b in the glottis category </C> <E> means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures </E>.",
    "<C> T1 in the subglottis category </C> <E> means the tumor is limited to the subglottis </E>.",
    "<C> T2 in the subglottis category </C> <E> means the tumor extends to vocal cord(s) with normal or impaired mobility </E>.",
    "<C> T3 in the subglottis category </C> <E> means the tumor is limited to the larynx with vocal cord fixation and/or inner cortex of the thyroid cartilage </E>.",
    "<C> T4 in the subglottis category </C> <E> means the tumor is moderately advanced or very advanced </E>.",
    "<C> T4a in the subglottis category </C> <E> means the tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx </E>.",
    "<C> T4b in the subglottis category </C> <E> means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures </E>.",
    "<CO> After induction chemotherapy </CO>, <E> 54% of patients developed a complete remission in the area of the primary tumour </E>.",
    "<CO> After induction chemotherapy </CO>, <E> 43% of patients developed a complete remission in the area of the primary tumour and the locoregional lymphatic drainage pathways </E>.",
    "<CO> After five years </CO>, <E> there was no significant difference in survival between the two study arms (30% versus 35% in the surgical arm) </E>.",
    "<CO> The 3- and 5-year survival rates with functional larynx </CO> were <E> 42% and 35%, respectively </E>.",
    "<CO> In patients who achieved complete remission after induction chemotherapy and subsequently received only radiotherapy </CO>, <E> a functional larynx was still present in 58% of patients after 5 years </E>.",
    "<C> A taxane-containing chemotherapy protocol </C> has proven to be <E> advantageous for functional laryngeal preservation </E> using <CO> induction chemotherapy </CO>.",
    "<C> The additional application of docetaxel during induction therapy </C> <A> increased </A> <E> the laryngeal preservation rate 3 years after therapy from 57.5% to 70.3% </E>."
]